Navigation Links
BRIDION(R) (sugammadex) Injection - First and Only Selective Relaxant Binding Agent - Approved in European Union
Date:7/29/2008

or coughing during the anesthetic procedure or during surgery, grimacing, or suckling on the endotracheal tube. In a few individuals, allergic-like reactions (i.e. flushing, erythematous rash) following sugammadex were reported.

About ESMERON

ESMERON (rocuronium bromide) is a non-depolarizing muscle relaxant. It was introduced in Europe 1994 and is one of the most widely used muscle relaxants in the United States, Canada (where it is marketed under the brand name ZEMURON) and many European countries. It was approved for use in Japan in July 2007 under the brand name ESLAX.

For full Prescribing Information please go to http://www.esmeron.com.

About Schering-Plough

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., USA, and its Web site is http://www.schering-plough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the plans for, the potential of and the potential market for BRIDION. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially f
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
2. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
3. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
4. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
5. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
6. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
7. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
8. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
9. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
10. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
11. CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 18, 2013  Specialty Coating Systems is ... Parylene coating technologies: SCS microRESIST™ Antimicrobial Parylene ... Parylene with antimicrobial properties to effectively eliminate ... (Logo: http://photos.prnewswire.com/prnh/20130618/DE33772LOGO ) ... and continue to pose a challenge to ...
(Date:6/18/2013)... 18, 2013 MPR is excited to unveil ... edition. It,s all part of an ongoing effort to freshen ... practitioners for over 28 years. (Photo: ... evolution MPR has expanded upon its foundation as ... to include an increasing array of clinical and practice management ...
(Date:6/18/2013)... INDIANAPOLIS , June 18, 2013 The ... LLY ) has declared a dividend for ... on outstanding common stock. The dividend ... at the close of business on August 15, 2013. ... a growing portfolio of pharmaceutical products by applying the ...
Breaking Medicine Technology:Specialty Coating Systems Announces New Antimicrobial Parylene Technology 2MPR Sports a Bold New Look 2
... ® Products is pleased to announce ... was developed to support the recent introduction of LimbO Waterproof Protectors ... Products in the United Kingdom, LimbO Waterproof Protectors enable children and ... cast or a bandage. The waterproof cover is simply slipped on ...
... CITY, Feb. 21, 2012 Genomma Lab Internacional, S.A.B. de ... a non-binding proposal to acquire all of the outstanding shares ... ) common stock for $16.60 dollars per share in cash. ... including Prestige,s net debt. Genomma,s all-cash proposal ...
Cached Medicine Technology:LimbO® Products Launches New U.S. Website 2Genomma Lab Internacional Announces Non-binding Proposal to Acquire Prestige Brands Holdings for $16.60 Per Share in Cash 2Genomma Lab Internacional Announces Non-binding Proposal to Acquire Prestige Brands Holdings for $16.60 Per Share in Cash 3Genomma Lab Internacional Announces Non-binding Proposal to Acquire Prestige Brands Holdings for $16.60 Per Share in Cash 4Genomma Lab Internacional Announces Non-binding Proposal to Acquire Prestige Brands Holdings for $16.60 Per Share in Cash 5
(Date:6/18/2013)... 2013 Senior drug regulatory officials from mainland ... to discuss—for the first time in the U.S.—the need for ... the regulatory process in a timely manner. Representatives from the ... respective best practices and processes in drug review during the ... at the DIA 2013 49th Annual Meeting . ...
(Date:6/18/2013)... Seven-year-old Riley Salz of Encino, California, is ... 40 hours a week of applied behavior analysis (ABA) ... for Autism and Related Disorders (CARD). Riley has been ... experienced remarkable progress, including learning to speak, starting conversations, ... journey through autism is now featured in CARD’s “Mission ...
(Date:6/18/2013)... have discovered and mapped the signaling network between two ... could cut off cancer cell growth at its starting ... University of Texas MD Anderson Cancer Center reported the ... cancer drug target, and MCM7, a protein vital to ... issue of Cancer Cell . , "MCM7 overexpression ...
(Date:6/18/2013)... Two months ago, Suyima Torres, 28, died from respiratory ... of a silicone treatment for gluteus augmentation at Cuerpos Health ... by a mystery Venezuelan doctor in a center that was ... Vazquez of Bayshore Cosmetic Surgery , women suffering from ... not board certified is more common than people think. ...
(Date:6/18/2013)... 18, 2013 David Connett, DO, vice ... Medicine for the College of Osteopathic Medicine of the ... been elected president of the Osteopathic Medical Board ... Jr. appointed Connett, a 1984 alumnus of COMP, to ... elected Connett to the position during a conference call. ...
Breaking Medicine News(10 mins):Health News:Renowned Regulatory Representatives From Mainland China and Taiwan to Discuss Need for Collaboration at DIA Meeting 2Health News:June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy 2Health News:June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy 3Health News:Scientists catch EGFR passing a crucial message to cancer-promoting protein 2Health News:Dr. Bernabe Vazquez Speaks on Miami Woman’s Deadly Silicone Butt Injection 2Health News:Dr. Bernabe Vazquez Speaks on Miami Woman’s Deadly Silicone Butt Injection 3
... China should focus on providing affordable medical care for the ... the wealthy minority, the country's health minister said.// ... medical equipment, trying to keep pace with developed countries, and ... Qiang said at a national health conference Saturday, says a ...
... in-hospital cardiac arrests than adults; with appropriate cardiopulmonary resuscitation ... previously thought.// ,These are some findings of ... supervised by Robert A. Berg, MD, professor of pediatrics ... of Medicine. ,The study results have been ...
... Union Minister for Health and Family Welfare, announced that the ... phase of the Reproductive and Child Health Programme called RCH-II.// ... All India Congress of Obstetrics and Gynaecology in Kochi yesterday. ... sector was to reduce the Maternal Mortality Rate, which was ...
... be maintained by a low fat diet into old age, ... counting is unnecessary. The study on nearly 50,000 post-menopausal women ... of the American Medical Association (JAMA), comes to the conclusion ... daily calories was enough to maintain a stable weight. ...
... revealed that more devastating earthquakes are likely to take place ... // They will inflict far greater damage than the 8 ... Bilham who has been working in quake-affected areas of Pakistan ... of energy was stored in the fault line in the ...
... (FOBT) is a simpler way of identifying individuals who ... published online in The Lancet Oncology.// Conventionally, guaiac FOBT ... this cancer, but this new test "could decrease substantially ... for colorectal cancer." ,Lead author Dr Callum G ...
Cached Medicine News:Health News:After Cardiac Arrest, Children Fare Better Than Adults 2Health News:More Severe Earthquakes May Hit Kashmir In Future 2
The AcuMatch M-Series modular femoral stem is a unique, innovative three-piece modular stem designed to address even the most complicated of clinical indications....
The link classic plus hip stem for cemented primary hip replacement surgery...
The uncemented hip joint prosthesis system....
The cemented hip joint prosthesis system....
Medicine Products: